{"id":40455,"date":"2025-09-01T13:54:06","date_gmt":"2025-09-01T05:54:06","guid":{"rendered":"https:\/\/flcube.com\/?p=40455"},"modified":"2025-09-01T13:54:07","modified_gmt":"2025-09-01T05:54:07","slug":"eisai-biogen-secure-fda-approval-for-lecanemab-auto%e2%80%91injector-home%e2%80%91based-alzheimers-therapy","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=40455","title":{"rendered":"Eisai &amp; Biogen Secure FDA Approval for Lecanemab Auto\u2011Injector \u2013 Home\u2011Based Alzheimer\u2019s Therapy"},"content":{"rendered":"\n<p>Japan-based Eisai (<a href=\"https:\/\/www.google.com\/finance\/quote\/4523:TYO\">TYO: 4523<\/a>) and US-based Biogen (<a href=\"https:\/\/www.google.com\/finance\/quote\/BIIB:NASDAQ\">NASDAQ: BIIB<\/a>) announced that the U.S. Food and Drug Administration (FDA) has granted approval for the subcutaneous auto\u2011injector formulation of lecanemab (brand name <strong>LEQEMB<\/strong>), sold under the product name <strong>IQLIK<\/strong>. The device is cleared for maintenance therapy in early Alzheimer\u2019s disease (AD) and is set to launch in the United States on <strong>October\u202f6\u202f2025<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-why-iqlik-matters\">Why IQLIK Matters<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>First\u2011in\u2011class home delivery<\/strong> \u2013 The 360\u202fmg\/1.8\u202fmL (200\u202fmg\/mL) dose can be administered in ~15\u202fseconds, eliminating the need for frequent clinic visits.<\/li>\n\n\n\n<li><strong>Comparable efficacy<\/strong> \u2013 Data from the Clarity\u202fAD trial and its open\u2011label extension demonstrate that the subcutaneous (SC\u2011AI) route matches the intravenous (IV) formulation in both clinical outcomes and biomarker reduction.<\/li>\n\n\n\n<li><strong>Safety advantage<\/strong> \u2013 Systemic reaction rates fall below 1\u202f% with SC delivery versus 26\u202f% with IV infusions, a substantial reduction in infusion\u2011related events.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-how-lecanemab-works\">How Lecanemab Works<\/h2>\n\n\n\n<p>Lecanemab is a monoclonal antibody that selectively binds amyloid\u2011beta (A\u03b2) proto\u2011fibrils, promoting clearance of neurotoxic plaques and slowing disease progression in patients with mild cognitive impairment or mild dementia.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-implications\">Market Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Patient convenience<\/strong> \u2013 Home\u2011based dosing empowers patients and caregivers, potentially improving adherence and reducing healthcare costs.<\/li>\n\n\n\n<li><strong>Competitive edge<\/strong> \u2013 The FDA approval positions Eisai\u2011Biogen at the forefront of AD therapeutics, offering a differentiated product in a rapidly expanding market.<\/li>\n\n\n\n<li><strong>Future pipeline<\/strong> \u2013 The success of IQLIK may accelerate the development of additional subcutaneous biologics for neurodegenerative disorders.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/li>\n<\/ul>\n","protected":false},"excerpt":{"rendered":"<p>Japan-based Eisai (TYO: 4523) and US-based Biogen (NASDAQ: BIIB) announced that the U.S. Food and&#8230;<\/p>\n","protected":false},"author":1,"featured_media":40456,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[351,350,993,15,1151],"class_list":["post-40455","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-biogen","tag-eisai","tag-nasdaq-biib","tag-product-approvals","tag-tyo-4523"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Eisai &amp; Biogen Secure FDA Approval for Lecanemab Auto\u2011Injector \u2013 Home\u2011Based Alzheimer\u2019s Therapy - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"The FDA has approved the IQLIK subcutaneous auto\u2011injector (LEQEMB) from Eisai and Biogen for maintenance treatment of early Alzheimer\u2019s disease. Launch slated for Oct\u202f6\u202f2025, the 360\u202fmg dose offers comparable efficacy to IV therapy with markedly lower systemic reactions.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=40455\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Eisai &amp; Biogen Secure FDA Approval for Lecanemab Auto\u2011Injector \u2013 Home\u2011Based Alzheimer\u2019s Therapy\" \/>\n<meta property=\"og:description\" content=\"The FDA has approved the IQLIK subcutaneous auto\u2011injector (LEQEMB) from Eisai and Biogen for maintenance treatment of early Alzheimer\u2019s disease. Launch slated for Oct\u202f6\u202f2025, the 360\u202fmg dose offers comparable efficacy to IV therapy with markedly lower systemic reactions.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=40455\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-09-01T05:54:06+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-09-01T05:54:07+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/0101.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40455#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40455\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Eisai &amp; Biogen Secure FDA Approval for Lecanemab Auto\u2011Injector \u2013 Home\u2011Based Alzheimer\u2019s Therapy\",\"datePublished\":\"2025-09-01T05:54:06+00:00\",\"dateModified\":\"2025-09-01T05:54:07+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40455\"},\"wordCount\":252,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40455#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/0101.webp\",\"keywords\":[\"Biogen\",\"Eisai\",\"NASDAQ: BIIB\",\"Product approvals\",\"TYO: 4523\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=40455#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40455\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=40455\",\"name\":\"Eisai &amp; Biogen Secure FDA Approval for Lecanemab Auto\u2011Injector \u2013 Home\u2011Based Alzheimer\u2019s Therapy - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40455#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40455#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/0101.webp\",\"datePublished\":\"2025-09-01T05:54:06+00:00\",\"dateModified\":\"2025-09-01T05:54:07+00:00\",\"description\":\"The FDA has approved the IQLIK subcutaneous auto\u2011injector (LEQEMB) from Eisai and Biogen for maintenance treatment of early Alzheimer\u2019s disease. Launch slated for Oct\u202f6\u202f2025, the 360\u202fmg dose offers comparable efficacy to IV therapy with markedly lower systemic reactions.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40455#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=40455\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40455#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/0101.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/0101.webp\",\"width\":1080,\"height\":608,\"caption\":\"Eisai & Biogen Secure FDA Approval for Lecanemab Auto\u2011Injector \u2013 Home\u2011Based Alzheimer\u2019s Therapy\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40455#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Eisai &amp; Biogen Secure FDA Approval for Lecanemab Auto\u2011Injector \u2013 Home\u2011Based Alzheimer\u2019s Therapy\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Eisai &amp; Biogen Secure FDA Approval for Lecanemab Auto\u2011Injector \u2013 Home\u2011Based Alzheimer\u2019s Therapy - Insight, China&#039;s Pharmaceutical Industry","description":"The FDA has approved the IQLIK subcutaneous auto\u2011injector (LEQEMB) from Eisai and Biogen for maintenance treatment of early Alzheimer\u2019s disease. Launch slated for Oct\u202f6\u202f2025, the 360\u202fmg dose offers comparable efficacy to IV therapy with markedly lower systemic reactions.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=40455","og_locale":"en_US","og_type":"article","og_title":"Eisai &amp; Biogen Secure FDA Approval for Lecanemab Auto\u2011Injector \u2013 Home\u2011Based Alzheimer\u2019s Therapy","og_description":"The FDA has approved the IQLIK subcutaneous auto\u2011injector (LEQEMB) from Eisai and Biogen for maintenance treatment of early Alzheimer\u2019s disease. Launch slated for Oct\u202f6\u202f2025, the 360\u202fmg dose offers comparable efficacy to IV therapy with markedly lower systemic reactions.","og_url":"https:\/\/flcube.com\/?p=40455","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-09-01T05:54:06+00:00","article_modified_time":"2025-09-01T05:54:07+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/0101.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=40455#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=40455"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Eisai &amp; Biogen Secure FDA Approval for Lecanemab Auto\u2011Injector \u2013 Home\u2011Based Alzheimer\u2019s Therapy","datePublished":"2025-09-01T05:54:06+00:00","dateModified":"2025-09-01T05:54:07+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=40455"},"wordCount":252,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=40455#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/0101.webp","keywords":["Biogen","Eisai","NASDAQ: BIIB","Product approvals","TYO: 4523"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=40455#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=40455","url":"https:\/\/flcube.com\/?p=40455","name":"Eisai &amp; Biogen Secure FDA Approval for Lecanemab Auto\u2011Injector \u2013 Home\u2011Based Alzheimer\u2019s Therapy - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=40455#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=40455#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/0101.webp","datePublished":"2025-09-01T05:54:06+00:00","dateModified":"2025-09-01T05:54:07+00:00","description":"The FDA has approved the IQLIK subcutaneous auto\u2011injector (LEQEMB) from Eisai and Biogen for maintenance treatment of early Alzheimer\u2019s disease. Launch slated for Oct\u202f6\u202f2025, the 360\u202fmg dose offers comparable efficacy to IV therapy with markedly lower systemic reactions.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=40455#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=40455"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=40455#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/0101.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/0101.webp","width":1080,"height":608,"caption":"Eisai & Biogen Secure FDA Approval for Lecanemab Auto\u2011Injector \u2013 Home\u2011Based Alzheimer\u2019s Therapy"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=40455#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Eisai &amp; Biogen Secure FDA Approval for Lecanemab Auto\u2011Injector \u2013 Home\u2011Based Alzheimer\u2019s Therapy"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/0101.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/40455","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=40455"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/40455\/revisions"}],"predecessor-version":[{"id":40457,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/40455\/revisions\/40457"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/40456"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=40455"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=40455"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=40455"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}